Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort
- Design
- Retrospective cohort · 107 participants · Mixed outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all participants had type 2 diabetes; the primary group was aged ≥65 years but BMI was not reported.
- Could weight loss explain it?
- Not applicableThe main outcomes are themselves weight and HbA1c change (with persistence), so mediation by weight loss is not a separate question; no mediation analysis was reported.
- Study tier
- Study tier 4VERY_LOW: a single-centre retrospective cohort with 37 older adults in the primary analysis and no untreated comparison group.
- Assessment
- Version 4 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This single-centre retrospective study in Japan followed adults with type 2 diabetes who took low-dose tirzepatide (107 people), focusing on 37 aged 65 or over. Among them, 23/37 (62.2%) met the combined goal of staying on treatment without stopping for side effects and reaching a weight or HbA1c target; median weight change was -3.07%, median HbA1c change was -1.0 percentage point, and 2/37 (5.4%) stopped because of side effects. There was no untreated comparison group, so these are observational findings, not proof that the drug caused the changes.
01Findings
What the study reported
- Drugs
- Tirzepatide
- Dose
- maximum observed dose of ≤5 mg/week through week 28
- Comparator
- no untreated comparator; younger adults used as contextual comparators with overlap weighting
- Primary outcome
- composite in adults aged ≥65 years: persistence, no AE-related discontinuation, and either ≥3% weight loss or HbA1c reduction ≥1.0 percentage point
- Effect
- Primary endpoint met by 23/37 (62.2%); 33/37 (89.2%) persisted; 2/37 (5.4%) stopped for AEs; median weight change -3.07%; median HbA1c change -1.0 percentage point; 19/37 (51.4%) reached HbA1c <7.0%; no clear age-related attenuation
- 95% confidence interval
- not reported in abstract
- Follow-up
- through week 28
- Adverse events
- 2/37 (5.4%) older adults discontinued because of AEs; renal, hydration and nutritional laboratory markers remained generally stable
- Limitations
- Single-centre retrospective study with 37 older adults in the primary analysis, no untreated comparison group and a selected low-dose population; results are observational through week 28.
Who was studied
- Age range
- ≥65 years in the primary-endpoint group of 37; younger adults also in the cohort
- Obesity status
- not reported in abstract
- Diabetes status
- type 2 diabetes required
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- type 2 diabetes
- Sample size
- 107
- Inclusion exclusion
- Japanese adults with type 2 diabetes starting tirzepatide April 2024 to December 2025 with maximum observed dose ≤5 mg/week through week 28
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 107
- Randomization
- no
- Blinding
- n/a
- Comparator
- no untreated comparator; younger adults used as contextual comparators with overlap weighting
- Follow up duration
- through week 28
- Outcome type
- mixed
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported; counts and percentages in 37 older adults
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[OBJECTIVE] To evaluate the clinical feasibility of a low-dose tirzepatide strategy in older adults with type 2 diabetes mellitus in routine outpatient practice. [METHODS] This single-center retrospective cohort included Japanese adults who initiated tirzepatide between April 2024 and December 2025 and received a maximum observed dose of ≤5 mg/week through week 28. The primary endpoint in adults aged ≥65 years combined treatment persistence, absence of adverse event (AE)-related discontinuation, and either ≥3% weight loss or an HbA1c reduction ≥1.0 percentage point (≥11 mmol/mol). Younger adults were contextual comparators using overlap weighting. [RESULTS] Among 122 tirzepatide initiators, 107 were included in the low-dose strategy cohort, including 37 older adults. The primary endpoint was achieved by 23/37 (62.2%); 33/37 (89.2%) remained on treatment, and 2/37 (5.4%) discontinued because of AEs. Median body weight change was -3.07%, median HbA1c change was -1.0 percentage point (-11 mmol/mol), and 19/37 (51.4%) achieved HbA1c <7.0% (<53 mmol/mol). Renal, hydration, and nutritional laboratory markers remained generally stable. Overlap-weighted comparisons showed no clear age-related attenuation. [CONCLUSION] In selected older adults, low-dose tirzepatide provided modest metabolic benefit with high persistence and infrequent AE-related discontinuation.